Ca2+ sensitizers: An emerging class of agents for counterbalancing weakness in skeletal muscle diseases?

Neuromuscular Disorders

Volumn 20, Issue 2, 2010, Pages 98-101

  Ochala, Julien ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ca2+ sensitizing agents; Myopathies; Skeletal muscle; Weakness

Indexed keywords

1,3,5,6 TETRAHYDRO 5 METHYL 6 PHENYL 3,6 METHANO 1,5 BENZODIAZOCINE 2,4 DIONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; 6 [1 [2 (4 CYANOPHENYL) 2 HYDROXYETHYL] 1,2,5,6 TETRAHYDRO 4 PYRIDYL] 4,5 DIHYDRO 3(2H) PYRIDAZINONE; CALCIUM CHANNEL AFFECTING AGENT; CALCIUM ION; CALCIUM SENSITIZER; CK 1909178; CONTRACTILE PROTEIN; LEVOSIMENDAN; N HYDROXY 5,6 DIMETHOXY 2 BENZO[B]THIOPHENECARBOXIMIDAMIDE; PIMOBENDAN; UNCLASSIFIED DRUG; CALCIUM; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; QUINOLINE DERIVATIVE; SIMENDAN; THIADIAZINE DERIVATIVE;

CALCIUM BINDING; CALCIUM SIGNALING; CELL FUNCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; HEART DISEASE; HUMAN; INOTROPISM; MUSCLE CELL; MUSCLE CONTRACTION; MUSCLE WEAKNESS; MYOPATHY; NEMALINE MYOPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKELETAL MUSCLE; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; MUSCLE DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

CALCIUM; CALCIUM SIGNALING; CARDIOTONIC AGENTS; CONTRACTILE PROTEINS; HUMANS; HYDRAZONES; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DISEASES; PYRIDAZINES; QUINOLINES; THIADIAZINES;

EID: 75149126663     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2009.11.010     Document Type: Review

References (29)

1. 2+ ions in excitation-contraction coupling of skeletal muscle fibres. Biochim Biophys Acta 1241 (1995) 59-116
2. Gordon A.M., Homsher E., and Regnier M. Regulation of contraction in striated muscle. Physiol Rev 80 (2000) 853-924
3. 2+-activation of striated muscle contraction. Biophys J 46 (1984) 541-543
4. Levine S., Nguyen T., Taylor N., et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med 358 (2008) 1327-1335
5. Ottenheijm C.A., Heunks L.M., Sieck G.C., et al. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 (2005) 200-205
6. Levine S., Nguyen T., Kaiser L.R., et al. Human diaphragm remodeling associated with chronic obstructive pulmonary disease: clinical implications. Am J Respir Crit Care Med 168 (2003) 706-713
7. Larsson L., Li X., Edstrom L., et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med 28 (2000) 34-45
8. 2+ activation of force generation in single human skeletal muscle fibres. Exp Physiol 93 (2008) 486-495
9. Ochala J., Li M., Ohlsson M., et al. Defective regulation of contractile function in muscle fibres carrying an E41K beta-tropomyosin mutation. J Physiol 586 (2008) 2993-3004
10. Riley D.A., Bain J.L., Romatowski J.G., et al. Skeletal muscle fiber atrophy: altered thin filament density changes slow fiber force and shortening velocity. Am J Physiol Cell Physiol 288 (2005) 360-365
11. 2+ activation properties in human muscle fibers: effects of a 60-day bed rest and countermeasures. J Appl Physiol 106 (2009) 1086-1099
12. Toursel T., Bastide B., Stevens L., et al. Alterations in contractile properties and expression of myofibrillar proteins in wobbler mouse muscles. Exp Neurol 162 (2000) 311-320
13. Stevens L., Bastide B., Maurage C.A., et al. Childhood spinal muscular atrophy induces alterations in contractile and regulatory protein isoform expressions. Neuropathol Appl Neurobiol 34 (2008) 659-670
14. 2+ cycling in skeletal muscle. J Muscle Res Cell Motil 28 (2007) 259-274
15. Adhikari B.B., Regnier M., Rivera A.J., et al. Cardiac length dependence of force and force redevelopment kinetics with altered cross-bridge cycling. Biophys J 87 (2004) 1784-1794
16. 2+ on cross-bridge turnover kinetics in skinned single rabbit psoas fibers: implications for regulation of muscle contraction. Proc Natl Acad Sci USA 85 (1988) 3265-3269
17. 2+ sensitizers. Circ J 72 (2008) 1915-1925
18. Kass D.A., and Solaro R.J. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 113 (2006) 305-315
19. Suga H. Ventricular energetics. Physiol Rev 70 (1990) 247-277
20. Sorsa T., Heikkinen S., Abbott M.B., et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 276 (2001) 9337-9343
21. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 269 (1994) 28584-28590
22. Pan B.S., and Johnson R.G. Interaction of cardiotonic thiadiazinone derivatives with cardiac troponin C. J Biol Chem 271 (1996) 817-823
23. 2+ sensitizing drug EMD 57033. J Biol Chem 276 (2001) 25456-25466
24. van Hees H.W., Dekhuijzen P.N., and Heunks L.M. Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 179 (2009) 41-47
25. 2+-activation characteristics between rat diaphragm fibers. Am J Physiol Cell Physiol 287 (2004) 79-87
26. 2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest 118 (2008) 3893-3903
27. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 40 (2002) 323-338
28. Antoniades C., Antonopoulos A.S., Tousoulis D., et al. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system. Curr Drug Metab 10 (2009) 95-103
29. Ochala J, Radell PJ, Eriksson LI, et al. EMD 57033 partially reverses ventilator-induced diaphragm muscle fibre calcium desensitisation. Pflugers Arch, in press.